Latest news and press releases about Lexeo Therapeutics, Inc. Common Stock (LXEO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
Price
| Price | $4.16 |
| Market Cap | $327M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.52 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.85% |
| Return on Invested Capital | -39.33% |
| Return on Assets | -34.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AMRN · CAPR · CTNM · DBVT · KYTX · LRMR · MREO
Explore sector: Healthcare · Biotechnology
More sections of LXEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks